[go: up one dir, main page]

MX2022008203A - Tratamiento de trastornos cutaneos. - Google Patents

Tratamiento de trastornos cutaneos.

Info

Publication number
MX2022008203A
MX2022008203A MX2022008203A MX2022008203A MX2022008203A MX 2022008203 A MX2022008203 A MX 2022008203A MX 2022008203 A MX2022008203 A MX 2022008203A MX 2022008203 A MX2022008203 A MX 2022008203A MX 2022008203 A MX2022008203 A MX 2022008203A
Authority
MX
Mexico
Prior art keywords
skin
cantharidin
treatment
lesion
treating
Prior art date
Application number
MX2022008203A
Other languages
English (en)
Inventor
Howard Welgus
Matthew Gene Davidson
Jayson Michael Rieger
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Publication of MX2022008203A publication Critical patent/MX2022008203A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar una o más lesiones cutáneas usando cantaridina, así como composiciones, regímenes de tratamiento, kits, dispositivos y sistemas asociados; un método para tratar a un sujeto que tiene una o más lesiones cutáneas puede implicar la administración de una composición que comprende cantaridina a una o más lesiones cutáneas; el método puede permitir el tratamiento eficaz de la(s) lesión(es) cutánea(s) con efectos secundarios adversos mínimos o nulos (por ejemplo, efectos secundarios adversos graves, daño permanente del tejido dérmico, cicatrización, ampollas excesivas en la piel que rodea la lesión, cantaridina plasmática elevada concentración, exposición sistémica a la cantaridina); la eficacia y/o seguridad del tratamiento puede deberse a ciertas características de la composición y/o exposición prolongada de la(s) lesión(es) de la piel a la cantaridina; los métodos descritos en este documento pueden usarse para una amplia variedad de trastornos cutáneos, incluidos trastornos de la piel que afectan principalmente a la epidermis de la piel.
MX2022008203A 2017-06-06 2019-12-05 Tratamiento de trastornos cutaneos. MX2022008203A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762516061P 2017-06-06 2017-06-06

Publications (1)

Publication Number Publication Date
MX2022008203A true MX2022008203A (es) 2022-08-04

Family

ID=64565991

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019014667A MX393574B (es) 2017-06-06 2018-06-06 Tratamiento de trastornos cutaneos
MX2022008203A MX2022008203A (es) 2017-06-06 2019-12-05 Tratamiento de trastornos cutaneos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019014667A MX393574B (es) 2017-06-06 2018-06-06 Tratamiento de trastornos cutaneos

Country Status (10)

Country Link
US (2) US11147790B2 (es)
EP (1) EP3634370A4 (es)
JP (2) JP7280870B2 (es)
KR (2) KR20250008976A (es)
CN (1) CN111278414A (es)
AU (2) AU2018281313B2 (es)
CA (1) CA3065151A1 (es)
IL (2) IL314274A (es)
MX (2) MX393574B (es)
WO (1) WO2018226894A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308690B2 (en) 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin
CN111278414A (zh) 2017-06-06 2020-06-12 维里卡制药有限公司 皮肤病的治疗
CN110997054B (zh) 2017-06-15 2024-10-25 维里卡制药有限公司 用于治疗身体表面病症的装置和方法
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
WO2019070980A2 (en) 2017-10-04 2019-04-11 Verrica Pharmaceuticals, Inc. SYNTHESIS OF CANTHARIDINE

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US600556A (en) 1898-03-15 Pyroxylin compound
US1744893A (en) 1926-10-02 1930-01-28 George N Hein Hypodermic syringe
CH204207A (de) 1938-03-10 1939-04-30 Richard Graebener Fa Flaschenverschluss.
GB587994A (en) 1945-01-01 1947-05-12 Harry Milman Bickle Improvements relating to stoppers for bottles and other containers
GB1021968A (en) 1964-12-04 1966-03-09 Mini Cleans Ltd Liquid applicator
US3981924A (en) 1974-04-22 1976-09-21 International Flavors & Fragrances Inc. Diels-Alder adduct product
JPS51141863A (en) 1975-06-02 1976-12-07 Nippon Nohyaku Co Ltd Process for preparing organo-phosphoric acid esters
IL51209A (en) 1976-03-25 1981-02-27 Baxter Travenol Lab Blood filter
AU512465B2 (en) 1977-01-05 1980-10-09 Basf Aktiengesellschaft Manufacture of 3-halosulfonylthiophene-carboxylic acid derivatives
US4148924A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4299006A (en) 1980-02-19 1981-11-10 Cruz Miguel M Elastic drip guard for paint brushes
US4298752A (en) 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4413154A (en) 1982-09-27 1983-11-01 Mobil Oil Corporation Diels-Alder cyclodimerization over a carbon molecular sieve catalyst
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPH07112446B2 (ja) 1989-12-28 1995-12-06 小川化工株式会社 頭髪用液体化粧料塗布具
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5296234A (en) 1991-10-11 1994-03-22 Abbott Laboratories Holder and packaging for a hardened medicated matrix
JPH05255367A (ja) 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
WO1995005156A1 (en) 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5464855A (en) 1994-08-09 1995-11-07 Warner-Lambert Company Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2736622B1 (fr) 1995-07-12 1997-08-29 Oreal Dispositif de conditionnement et de distribution d'un produit liquide ou pateux avec applicateur en forme de dome
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6066124A (en) 1998-11-24 2000-05-23 Caillouette; James C. Control of treatment fluid application to tissue
US6379342B1 (en) 1999-04-02 2002-04-30 Scion International, Inc. Ampoule for dispensing medication and method of use
USD436661S1 (en) 1999-05-20 2001-01-23 Melvin P Berry Suppository applicator
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
JP2001245964A (ja) 2000-03-02 2001-09-11 Lion Corp 芳香・消臭剤
FR2808662B1 (fr) 2000-05-09 2002-12-20 Delviel Systeme d'application d'une composition sur un element de surface
DE20016131U1 (de) 2000-09-16 2000-11-23 Aesculap AG & Co. KG, 78532 Tuttlingen Applikator für Gewebekleber
CN1237065C (zh) 2001-05-31 2006-01-18 香港中文大学 含有与含铂抗癌药物组合的去甲基斑蟊素的组合物及其用途
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6547467B2 (en) 2001-08-29 2003-04-15 Closure Medical Corporation Microapplicators, delivery systems and methods for adhesives and sealants
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
BRPI0213658A8 (pt) 2001-10-19 2016-12-06 F Hoffmann La Roche Ltd Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resíduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isômero ou com z-isômero de análogos de ciclosporina a modificados no resíduo de 1-aminoácido, mistura de (e) e (z)-isômeros, composição, método para a síntese estereoseletiva do z-isômero de isatx247, método para a preparação de aldeído do ciclosporina a
JP4739621B2 (ja) 2001-12-25 2011-08-03 株式会社ダイヘン 消耗電極式アーク溶接装置
US20040011830A1 (en) 2002-07-17 2004-01-22 Kim Su Heon Dosing dispenser including multifunction cap
JP2004059446A (ja) 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
US20040162533A1 (en) 2003-02-06 2004-08-19 Alley Kenneth A. Applicator device
CA2520921A1 (en) 2003-03-31 2004-10-21 Nick J. Manesis Multi-dose liquid dispensing assembly
RU2326893C2 (ru) 2003-04-16 2008-06-20 Кориум Интернэшнл Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними
US7909808B2 (en) 2003-06-13 2011-03-22 Medlogic Global Limited Dual-ended applicator for dispensing two fluids
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
KR20050032154A (ko) 2003-10-01 2005-04-07 나건연 약물, 화장품 도포기
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
FR2872704B1 (fr) 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US7846140B2 (en) 2004-11-30 2010-12-07 James Hagele Mini eye drop tip
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
US20070275045A1 (en) * 2006-02-28 2007-11-29 Evans Robin D Composition for the treatment of warts and molluscum contagiosum
US7563256B2 (en) 2006-03-30 2009-07-21 Isaac Hearne Cannula tip eye drop dispenser
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
US7758553B2 (en) 2006-04-03 2010-07-20 Insight Vision Incorporated Drop dispenser for the delivery of uniform droplets of viscous liquids
CN101453923A (zh) 2006-05-29 2009-06-10 三菱铅笔株式会社 涂敷工具及涂敷物质容器
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
JP5230023B2 (ja) 2007-01-25 2013-07-10 ハイパーブランチ メディカル テクノロジー， インコーポレイテッド 複数成分製剤などのための塗布器および使用方法
CN100545164C (zh) 2007-02-13 2009-09-30 北京世纪博康医药科技有限公司 斑蝥酸钠的制备工艺
KR101329489B1 (ko) 2007-04-04 2013-11-13 엘지전자 주식회사 냉장고용 홈바
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
KR100786203B1 (ko) 2007-05-14 2007-12-17 이민영 순간 접착제 용기
CN101108854B (zh) 2007-07-27 2010-05-26 贵州大学 一种斑蝥素分离纯化方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
CN100577665C (zh) 2007-08-16 2010-01-06 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
EP2307558A4 (en) 2008-07-03 2012-08-08 Allelogic Biosciences Corp COMPOSITIONS AND PROCEDURES FOR THE PROTECTION OF NUCLEOPHILER GROUPS
WO2010079513A2 (en) * 2009-01-07 2010-07-15 Sanjay Banerji Painless treatment of warts, corns & callus
US9480691B1 (en) 2009-01-20 2016-11-01 Hill Dermaceuticals, Inc. Topical liquid containing refined peanut oil for treating skin proliferation or inflammation disorders
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
CN102480945A (zh) 2009-06-03 2012-05-30 艾克斯特克有限责任公司 皮肤处理组合物
EP2477493A1 (en) 2009-09-16 2012-07-25 Cylene Pharmaceuticals, Inc. Novel tricyclic protein kinase modulators
RU2552470C2 (ru) 2009-10-08 2015-06-10 Эм Эс Ди Консьюмер Кэар, Инк. Композиция с низким содержанием простого эфира и устройство для ее доставки
CN101798309A (zh) 2009-12-04 2010-08-11 南京泽朗医药科技有限公司 一种从斑蝥中制备斑蝥素的方法
US9918991B2 (en) 2010-01-14 2018-03-20 Hydromer, Inc. Topical antimicrobial compositions and methods of using same
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
JP5736730B2 (ja) 2010-10-29 2015-06-17 王子ホールディングス株式会社 粘着シート
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) * 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN102336765A (zh) 2011-10-11 2012-02-01 江苏四环生物股份有限公司 从斑蝥中提取斑蝥素的方法
CN102526146B (zh) 2012-01-13 2014-02-26 苏州大学 含有人参皂苷和斑蝥素的药物组合物及其用途
CA2869232A1 (en) 2012-06-19 2013-12-27 F. Hoffmann-La Roche Ag New bicyclic thiophenylamide compounds
CN202730045U (zh) 2012-08-13 2013-02-13 遵义医学院 一种斑蝥素分离纯化的装置
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
AU2014308690B2 (en) * 2013-08-21 2019-07-18 Verrica Pharmaceuticals, Inc. Compositions, methods and systems for the treatment of cutaneous disorders
EP3134061B1 (en) 2014-04-21 2020-10-07 Aclaris Therapeutics, Inc. Peroxide formulations and methods and applicators for using the same
CN103923095A (zh) 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙
JP6081670B2 (ja) 2014-07-11 2017-02-15 株式会社メニコン 視認性確保材および視認性確保材吐出装置
WO2016061193A1 (en) 2014-10-15 2016-04-21 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
JP6810693B2 (ja) 2014-12-17 2021-01-06 ヴェリカ ファーマシューティカルズ, インコーポレイテッドVerrica Pharmaceuticals, Inc. カンタリジンおよび生理活性カンタリジン誘導体の商業的に実現可能な合成
US11168091B2 (en) 2015-01-20 2021-11-09 Verrica Pharmaceuticals Inc. Quantification and preparation of pharmaceutical grade cantharidin
WO2016134130A1 (en) * 2015-02-20 2016-08-25 Pedicis Research Llc Compositions and methods for treatment of skin infections
CN204817029U (zh) 2015-06-30 2015-12-02 厦门建霖工业有限公司 一种过滤式保健莲蓬臂
USD772407S1 (en) 2015-12-22 2016-11-22 Adhezion Biomedical, Llc Liquid dispenser having a tapered tip
USD771250S1 (en) 2015-12-22 2016-11-08 Adhezion Biomedical, Llc Liquid dispenser with an extended tip
WO2017132221A1 (en) 2016-01-25 2017-08-03 Porex Corporation Multicomponent sintered porous liquid applicator nibs
USD801830S1 (en) 2016-05-19 2017-11-07 Adhezion Biomedical, Llc Liquid dispenser
CN106674248B (zh) 2016-12-17 2019-02-26 重庆市中药研究院 一种斑蝥素的合成工艺
CN111278414A (zh) 2017-06-06 2020-06-12 维里卡制药有限公司 皮肤病的治疗
CN110997054B (zh) 2017-06-15 2024-10-25 维里卡制药有限公司 用于治疗身体表面病症的装置和方法
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
WO2019070980A2 (en) 2017-10-04 2019-04-11 Verrica Pharmaceuticals, Inc. SYNTHESIS OF CANTHARIDINE
USD868160S1 (en) 2018-03-26 2019-11-26 Robert Lam Multi-nib marker
US20190315151A1 (en) 2018-04-17 2019-10-17 Crayola Llc Ink-based marking device having a multi-component nib structure
USD938587S1 (en) 2018-06-11 2021-12-14 Terumo Cardiovascular Systems Corporation Dissector cone for endoscope
USD933494S1 (en) 2018-07-10 2021-10-19 Aptar Radolfzell Gmbh Packaging bottle for liquids
EP3823555A1 (en) 2018-07-19 2021-05-26 Sanulus Medical, LLC Devices and methods for targeted delivery of a substance
USD947027S1 (en) 2020-02-11 2022-03-29 B.R. Tenant, Inc. Spout for a container
USD957625S1 (en) 2020-04-29 2022-07-12 Susan Reynolds Syringe

Also Published As

Publication number Publication date
MX393574B (es) 2025-03-24
AU2018281313A1 (en) 2019-12-19
IL270900B1 (en) 2024-08-01
WO2018226894A1 (en) 2018-12-13
EP3634370A1 (en) 2020-04-15
MX2019014667A (es) 2020-02-07
IL314274A (en) 2024-09-01
CN111278414A (zh) 2020-06-12
US11147790B2 (en) 2021-10-19
US20210401793A1 (en) 2021-12-30
WO2018226894A8 (en) 2019-01-31
IL270900B2 (en) 2024-12-01
US20200155498A1 (en) 2020-05-21
JP2023061951A (ja) 2023-05-02
CA3065151A1 (en) 2018-12-13
IL270900A (en) 2020-01-30
EP3634370A4 (en) 2021-03-03
US12233042B2 (en) 2025-02-25
KR102749015B1 (ko) 2025-01-02
KR20250008976A (ko) 2025-01-16
AU2024204696A1 (en) 2024-07-25
JP7280870B2 (ja) 2023-05-24
JP2020522578A (ja) 2020-07-30
KR20200050941A (ko) 2020-05-12
AU2018281313B2 (en) 2024-05-02
BR112019025625A2 (pt) 2020-06-16

Similar Documents

Publication Publication Date Title
MX2022008203A (es) Tratamiento de trastornos cutaneos.
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
CL2019000935A1 (es) Composición farmacéutica, métodos para tratamiento y usos de la misma.
CL2019000732A1 (es) Tratamiento avv de la enfermedad de huntington.
MX387788B (es) Uso de agentes activos durante tratamientos quimicos.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
NI201700137A (es) Derivados de indol mono o disustituidos como inhibidores de la replicaciã“n viral del dengue
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
MX391720B (es) Terapia combinada para tratar cáncer.
CO6531463A2 (es) Combinaciones de un inhibidor de pi3k y un inhibidor de mek
EA201591378A1 (ru) Композиции неорганических наночастиц в комбинации с ионизирующим излучением для лечения рака
BR112018001533A2 (pt) método de redução da necessidade de cirurgia em pacientes sofrendo da hiperplasia benigna da próstata
CO2021001172A2 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
MX2021004755A (es) Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria.
MX2021013901A (es) Composiciones y métodos para el tratamiento del cáncer.